Utility of Biomarkers in Cardiac Amyloidosis

JACC Heart Fail. 2020 Sep;8(9):701-711. doi: 10.1016/j.jchf.2020.03.007. Epub 2020 Jul 8.

Abstract

Cardiac amyloidosis is a growing field, with advancements in diagnosis and management. Cardiac biomarkers are used to predict survival and to develop severity staging systems. Cardiac biomarkers are also used in clinical practice to stratify patients for treatment and to evaluate response to therapies. The current review summarizes the major clinical utility of current biomarkers in patients with cardiac amyloidosis and provides insights about future areas of investigation.

Keywords: amyloidosis; biomarkers; light chains; transthyretin.

Publication types

  • Review

MeSH terms

  • Amyloidosis*
  • Biomarkers
  • Cardiomyopathies*
  • Heart Failure*
  • Humans

Substances

  • Biomarkers